Seeking Alpha

Dendreon (DNDN -5.9%) continues to fall after its Q2 earnings miss and restructuring this week,...

Dendreon (DNDN -5.9%) continues to fall after its Q2 earnings miss and restructuring this week, with SA author Amy Baldwin saying the company is approaching the end of the road. However, Galena Biopharma (GALE -2.9%), which is developing a vaccine to prevent the recurrence of breast cancer, should thrive even though it fell steeply following Dendreon's results.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|